Aura Biosciences Inc (AURA) Stock Price, Quote & News

Company Profile

Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 500 8864

Website: www.aurabiosciences.com

Address:

80 Guest Street, 5th Floor, Boston, United States

AtomicAIerts Dec. 5 at 11:32 AM

$AURA AtomicAlerts Scalp Alert Direction: LONG Entry: $6.45 TP1: $7.15 | TP2: $7.85 | TP3: $8.55 Stop Loss: $5.85 👉 https://atomicalerts.com

0 · Reply

JarvisFlow Nov. 26 at 12:15 PM

Evercore ISI Group updates rating for Aura Biosciences ( $AURA ) to Outperform, target set at 13.

0 · Reply

Iightning Nov. 26 at 5:08 AM

1ightning® Options Trade Alert (Actionable) | Buy $AURA Jan 16 $8 Call | Enter: $1.25 Exit: $1.90 | Profit: 51.61% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 25 at 3:16 PM

1ightning® Options Trade Alert (Actionable) | Buy $AURA Jan 16 $8 Call | Enter: $1.25 Exit: $1.90 | Profit: 51.61% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 25 at 4:11 AM

1ightning® Options Trade Alert (Actionable) | Buy $AURA Jan 16 $8 Call | Enter: $1.25 Exit: $1.90 | Profit: 51.61% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 22 at 1:22 AM

1ightning® Options Trade Alert (Actionable) | Buy $AURA Jan 16 $8 Call | Enter: $1.25 Exit: $2.07 | Profit: 65.89% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 21 at 4:44 AM

1ightning® Options Trade Alert (Actionable) | Buy $AURA Jan 16 $8 Call | Enter: $1.25 Exit: $2.07 | Profit: 65.89% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 20 at 2:24 AM

1ightning® Options Trade Alert (Actionable) | Buy $AURA Jan 16 $8 Call | Enter: $1.25 Exit: $2.07 | Profit: 65.89% ROI | https://1ightning.com

0 · Reply

BillionerOfKing Oct. 14 at 2:05 PM

$AURA Current Stock Price: $6.08 Contracts to trade: $5 AURA Oct 17 2025 Call Entry: $1.71 Exit: $2.71 ROI: 58% Hold ~20 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

Buysellbkr Oct. 13 at 10:26 PM

$AURA lets get 1.50

1 · Reply

Aura Biosciences to Participate in the 8th Annual Evercore Healthcare Conference

Nov 13, 2025, 7:00 AM EST - 21 days ago

Aura Biosciences Reports Third Quarter 2025 Financial Results and Business Highlights

Sep 3, 2025, 7:00 AM EDT - 3 months ago

Aura Biosciences to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Aug 13, 2025, 7:00 AM EDT - 4 months ago

Aura Biosciences Reports Second Quarter 2025 Financial Results and Business Highlights

May 15, 2025, 9:32 AM EDT - 7 months ago

Aura Biosciences Announces Pricing of Public Offering of Common Stock and Warrants

May 15, 2025, 6:10 AM EDT - 7 months ago

Aura Biosciences Announces Proposed Public Offering of Common Stock and Warrants

May 15, 2025, 6:01 AM EDT - 7 months ago

Aura Biosciences Reports First Quarter 2025 Financial Results and Business Highlights

May 1, 2025, 4:01 PM EDT - 7 months ago

Aura Biosciences to Participate in Upcoming Investor Conferences

Apr 2, 2025, 7:00 AM EDT - 8 months ago

Aura Biosciences Announces Appointment of Teresa Bitetti to Board of Directors

Mar 25, 2025, 6:58 PM EDT - 9 months ago

Aura Biosciences, Inc (AURA) Virtual Urologic Oncology Investor Event Call (Transcript)

Mar 24, 2025, 4:01 PM EDT - 9 months ago

Aura Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

Mar 24, 2025, 7:00 AM EDT - 9 months ago

Positive Data from Phase 1 Trial of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) Presented at the 40th Annual European Association of Urology Congress

Mar 3, 2025, 7:00 AM EST - 9 months ago

Aura Biosciences Announces Additional Data from Ongoing Phase 1 Trial in Non-Muscle Invasive Bladder Cancer to be Presented as a Late-Breaking Abstract at the 40th Annual European Association of Urology Congress

Dec 2, 2024, 4:31 AM EST - 1 year ago

Muscle Invasive Bladder Cancer Drug Pipeline Market Research 2024 Featuring Aura Biosciences, Janssen Research & Development, Asieris Pharmaceuticals, and RemeGen

Oct 21, 2024, 3:12 PM EDT - 1 year ago

Aura Biosciences: 2 Positive Bel-Sar Data Releases Brings Shareholder Value

Oct 18, 2024, 9:16 AM EDT - 1 year ago

Aura Biosciences' Bladder Cancer Candidate Demonstrates Tumor Shrinkage In Patients With High-Grade Disease

Oct 17, 2024, 4:05 PM EDT - 1 year ago

Multiple Clinical Complete Responses Demonstrated Following Single Low Dose Administration of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) in Ongoing Phase 1 Trial

Oct 15, 2024, 12:40 PM EDT - 1 year ago

3 Small-Cap Stocks Ready to Deliver Significant Growth

FBRT TZOO

Sep 20, 2024, 3:30 PM EDT - 1 year ago

Sept. 13-20 Undercovered Stock Picks: Aura Biosciences, APA Corporation, iTeos, CuriosityStream +

APA CURI

Sep 17, 2024, 12:31 PM EDT - 1 year ago

Aura Biosciences: Highly Derisked Late-Stage Eye Cancer Company

Sep 12, 2024, 11:40 AM EDT - 1 year ago

Aura Biosciences Touts Promising Data From Eye Cancer Candidate

Sep 12, 2024, 6:30 AM EDT - 1 year ago

Aura Biosciences Reports Positive Phase 2 End of Study Results Evaluating Bel-sar as a First-Line Treatment for Early-Stage Choroidal Melanoma

Sep 3, 2024, 4:05 PM EDT - 1 year ago

Aura Biosciences to Host a Urologic Oncology Investor Event to Present Early Non-Muscle Invasive Bladder Cancer (NMIBC) Data from its Ongoing Phase 1 Trial on Thursday, October 17, 2024

Aug 26, 2024, 4:05 PM EDT - 1 year ago

Aura Biosciences Announces the Presentation of Phase 2 End of Study Data Evaluating Suprachoroidal Administration of Bel-sar for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at The Retina Society Annual Meeting

Aug 8, 2024, 7:00 AM EDT - 1 year ago

Aura Biosciences Reports Second Quarter 2024 Financial Results and Business Highlights

May 30, 2024, 4:05 PM EDT - 1 year ago

Aura Biosciences to Participate in the Jefferies Global Healthcare Conference

May 23, 2024, 8:00 AM EDT - 1 year ago

Aura Biosciences to Host Virtual KOL Event “Pioneering a New Standard of Care In Ocular Oncology” on May 29, 2024

May 9, 2024, 7:00 AM EDT - 1 year ago

Aura Biosciences Reports First Quarter 2024 Financial Results and Business Highlights

Mar 27, 2024, 7:00 AM EDT - 1 year ago

Aura Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

Dec 7, 2023, 8:00 AM EST - 2 years ago

Aura Biosciences Announces First Patient Dosed in Global Phase 3 CoMpass Trial Evaluating the Safety and Efficacy of Belzupacap Sarotalocan (Bel-sar) for First-Line Treatment of Early-Stage Choroidal Melanoma

Nov 15, 2023, 8:23 AM EST - 2 years ago

Aura Biosciences: Mid-2024 Data Could Bring Expansion Opportunity

Nov 9, 2023, 4:05 PM EST - 2 years ago

Aura Biosciences Reports Third Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights

Nov 6, 2023, 10:02 PM EST - 2 years ago

Aura Biosciences Announces Pricing of Public Offering of Common Stock

Nov 6, 2023, 4:08 PM EST - 2 years ago

Aura Biosciences Announces Proposed Public Offering of Common Stock

Nov 6, 2023, 3:00 PM EST - 2 years ago

Aura Biosciences Receives FDA Agreement Under Special Protocol Assessment (SPA) for CoMpass Phase 3 Clinical Trial of Belzupacap Sarotalocan (Bel-sar) in Early-stage Choroidal Melanoma

Oct 31, 2023, 4:05 PM EDT - 2 years ago

Aura Biosciences to Present Updated Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (Bel-sar) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at AAO 2023

Oct 2, 2023, 4:05 PM EDT - 2 years ago

Aura Biosciences Strengthens and Expands Leadership Team with Key Appointments

Aug 9, 2023, 7:00 AM EDT - 2 years ago

Aura Biosciences Reports Second Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights

May 27, 2023, 8:00 AM EDT - 2 years ago

Aura Biosciences: Excellent Execution In The Large Ocular Cancer Market

May 12, 2023, 7:00 AM EDT - 2 years ago

Aura Biosciences to Participate in the JMP Securities Life Sciences Conference

May 11, 2023, 4:10 PM EDT - 2 years ago

Aura Biosciences Reports First Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights

Mar 15, 2023, 4:10 PM EDT - 2 years ago

Aura Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Development and Operational Highlights

Feb 16, 2023, 7:00 AM EST - 3 years ago

Aura Biosciences Announces Positive Interim Phase 2 Safety and Efficacy Data of Belzupacap Sarotalocan (Bel-sar) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma with Suprachoroidal Administration

Feb 10, 2023, 6:03 AM EST - 3 years ago

Why Shares of Aura Biosciences Jumped This Week

Nov 10, 2022, 7:00 AM EST - 3 years ago

Aura Biosciences Reports Third Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights

Nov 10, 2022, 6:45 AM EST - 3 years ago

Aura Announces Global Phase 3 Trial Design with Suprachoroidal Route of Administration Based on Positive Phase 2 Interim Data of Belzupacap Sarotalocan in Early-Stage Choroidal Melanoma

Oct 3, 2022, 7:00 AM EDT - 3 years ago

Aura Biosciences Announces Interim Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma Presented at AAO 2022

Sep 28, 2022, 7:00 AM EDT - 3 years ago

Aura Biosciences Announces First Patient Dosed in Phase 1 Study Evaluating Belzupacap Sarotalocan (AU-011) for the Treatment of Non-Muscle Invasive Bladder Cancer

Sep 27, 2022, 7:00 AM EDT - 3 years ago

Aura Biosciences to Present Ongoing Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at AAO 2022

Sep 7, 2022, 7:00 AM EDT - 3 years ago

Aura Biosciences to Present Phase 2 Safety Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) in Patients with Choroidal Melanoma at the ESMO 2022 Congress

AtomicAIerts Dec. 5 at 11:32 AM

$AURA AtomicAlerts Scalp Alert Direction: LONG Entry: $6.45 TP1: $7.15 | TP2: $7.85 | TP3: $8.55 Stop Loss: $5.85 👉 https://atomicalerts.com

0 · Reply

JarvisFlow Nov. 26 at 12:15 PM

Evercore ISI Group updates rating for Aura Biosciences ( $AURA ) to Outperform, target set at 13.

0 · Reply

Iightning Nov. 26 at 5:08 AM

1ightning® Options Trade Alert (Actionable) | Buy $AURA Jan 16 $8 Call | Enter: $1.25 Exit: $1.90 | Profit: 51.61% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 25 at 3:16 PM

1ightning® Options Trade Alert (Actionable) | Buy $AURA Jan 16 $8 Call | Enter: $1.25 Exit: $1.90 | Profit: 51.61% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 25 at 4:11 AM

1ightning® Options Trade Alert (Actionable) | Buy $AURA Jan 16 $8 Call | Enter: $1.25 Exit: $1.90 | Profit: 51.61% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 22 at 1:22 AM

1ightning® Options Trade Alert (Actionable) | Buy $AURA Jan 16 $8 Call | Enter: $1.25 Exit: $2.07 | Profit: 65.89% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 21 at 4:44 AM

1ightning® Options Trade Alert (Actionable) | Buy $AURA Jan 16 $8 Call | Enter: $1.25 Exit: $2.07 | Profit: 65.89% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 20 at 2:24 AM

1ightning® Options Trade Alert (Actionable) | Buy $AURA Jan 16 $8 Call | Enter: $1.25 Exit: $2.07 | Profit: 65.89% ROI | https://1ightning.com

0 · Reply

BillionerOfKing Oct. 14 at 2:05 PM

0 · Reply

Buysellbkr Oct. 13 at 10:26 PM

$AURA lets get 1.50

1 · Reply

BillionerOfKing Oct. 9 at 10:25 AM

$AURA Current Stock Price: $6.08 Contracts to trade: $5 AURA Oct 17 2025 Call Entry: $1.71 Exit: $3.39 ROI: 98% Hold ~31 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

Quantumup Oct. 7 at 12:18 PM

Citizens reiterated $IDYA Market Outperform-$45 and said, 'We Remain Bullish On IDYA's Upcoming ESMO Update That Can Help Investors To Estimate The PoS Of The Neoadjuvant Uveal Melanoma Opportunity.' $IMCR $AURA Citizens additionally said:

0 · Reply

Sillyspuh Oct. 2 at 7:56 PM

$AURA sleepy stock. will it ever wake up?

1 · Reply

WickRange Aug. 23 at 6:22 AM

$AURA Aura Biosciences is a clinical stage oncology company with novel virus-like drug conjugate platform

0 · Reply

d_risk Aug. 13 at 4:01 PM

$AURA - Aura Biosciences Inc. Common Stock - 10Q - Updated Risk Factors Aura’s latest 10-Q risk factors spotlight expanded challenges in bel-sar’s development, regulatory hurdles, and commercialization, heightened funding and dilution risks, new cybersecurity and disaster threats, increased operational and litigation exposures, and reduced insider control—underscoring deep financial and execution uncertainties ahead. #Biotechnology #OperationalRisk #Cybersecurity #FundingRisk #RegulatoryRisk 🟢 Added 🟠 Removed https://d-risk.ai/AURA/10-Q/2025-08-13

0 · Reply

Freddie___Mac Jul. 14 at 9:44 PM

$EYPT we are moving in the right direction... stock is up nicely since then. two under the radar names I recommend to look at are $DRTS and $AURA

2 · Reply

jayz_crypto Jul. 12 at 12:41 PM

$USELESS.X Useless aura $USERA JUST LAUNCHED ON PUMP.FUN THIS ONE BUILDING IN SILENCE Get in before dex and boost is paid at 20k 2 of the most hottest meme $USELESS and $AURA LOW MC 7K, GREAT ENTRY. GRAB A MOON BAG AND SEE WHAT HAPPENS. TEAM VERY ACTIVE AND MEMES AND ART ARE FIRE. DcHhSnBjmpE3iCnoeCfpqQKFfp8r7rxE5d7Tm26tpump https://dexscreener.com/solana/3MJsCbu7WbCp2xsDAQVQQruNi7oX9M4VKAWb9LnKYQmQ

0 · Reply

ExitSTRATjoe77 Jun. 18 at 7:30 PM

$AURA

0 · Reply

rando321456 Jun. 18 at 8:01 AM

$CLSD $AURA It was a few weeks ago but when Aura's ceo was talking about pricing they referenced the approved drug for the choroidal melanoma that has spread, which goes for about 600k before the patient dies. Am I off my rocker thinking that between choroidal melanoma and mets that they will just be doing 5 billion dollars in revenue if the data pattern holds?

1 · Reply

JarvisFlow Jun. 2 at 6:57 PM

JMP Securities has updated their rating for Aura Biosciences ( $AURA ) to Market Outperform with a price target of 19.

0 · Reply

JarvisFlow May. 23 at 1:23 PM

JMP Securities has updated their rating for Aura Biosciences ( $AURA ) to Market Outperform with a price target of 19.

0 · Reply

AZOZ May. 21 at 12:03 PM

$PAPL $RLMD $PSQH $AURA Insider's love it right now!

0 · Reply

Market Cap	382.29M
Revenue (ttm)	0.00
Net Income (ttm)	-86.92M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	117,700
Avg Vol	244,312
Day's Range	N/A - N/A
Shares Out	63.50M
Stochastic %K	76%
Beta	0.44
Analysts	Strong Sell
Price Target	$19.40